13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mean Platelet Volume Predicts Vascular Access Events in Hemodialysis Patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Arteriovenous fistula (AVF) and arteriovenous graft (AVG) is the vascular access (VA) of 78% of hemodialysis patients (HD) in France. VA dysfunction corresponding to either stenosis requiring angioplasty or acute thrombosis is responsible for 30% of hospitalizations. Mean platelet volume (MPV) is a biological marker of cardiovascular events. We studied MPV in a cohort of HD patients as a predictive marker of VA dysfunction. We conducted a prospective monocentric cohort study that included patients with AVF or AVG on chronic HD ( n = 153). The primary outcome was the incidence of VA dysfunction regarding MPV value. The median MPV was 10.8 fL (7.8–13.5), and four groups were designed according to MPV quartiles. Fifty-four patients experienced the first event of VA dysfunction. The incidence of VA dysfunction was higher in patients with the highest MPV: 59% (23 events), 34% (14 events), 27% (11 events), and 18% (6 events), respectively, for the fourth, third, second, and first quartiles ( p = 0.001). Multivariate analysis confirmed an independent association between MPV and VA dysfunction—OR 1.52 (1.13–2.07), p < 0.001. VA dysfunction is predicted by MPV level. Patients with the highest MPV have the highest risk of VA events.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis.

          To determine whether an association exists between mean platelet volume (MPV) and acute myocardial infarction (AMI) and other cardiovascular events. Platelet activity is a major culprit in atherothrombotic events. MPV, which is widely available in clinical practice, is a potentially useful biomarker of platelet activity in the setting of cardiovascular disease. We performed a systematic review and meta-analysis investigating the association between MPV and AMI, all-cause mortality following myocardial infarction, and restenosis following coronary angioplasty. Results were pooled using random-effects modeling. Pooled results from 16 cross-sectional studies involving 2809 patients investigating the association of MPV and AMI indicated that MPV was significantly higher in those with AMI than those without AMI [mean difference 0.92 fL, 95% confidence interval (CI) 0.67-1.16, P < 0.001). In subgroup analyses, significant differences in MPV existed between subjects with AMI, subjects with stable coronary disease (P < 0.001), and stable controls (P < 0.001), but not vs. those with unstable angina (P = 0.24). Pooled results from three cohort studies involving 3184 patients evaluating the risk of death following AMI demonstrated that an elevated MPV increased the odds of death as compared with a normal MPV (11.5% vs. 7.1%, odds ratio 1.65, 95% CI 1.12-2.52, P = 0.012). Pooled results from five cohort studies involving 430 patients who underwent coronary angioplasty revealed that MPV was significantly higher in patients who developed restenosis than in those who did not develop restenosis (mean difference 0.98 fL, 95% CI 0.74-1.21, P < 0.001). Elevated MPV is associated with AMI, mortality following myocardial infarction, and restenosis following coronary angioplasty. These data suggest that MPV is a potentially useful prognostic biomarker in patients with cardiovascular disease. Whether the relationship is causal, and whether MPV should influence practice or guide therapy, remains unknown.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            EBPG on Vascular Access.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Haemostasis in chronic kidney disease.

              The coagulation system has gained much interest again as new anticoagulatory substances have been introduced into clinical practice. Especially patients with renal failure are likely candidates for such a therapy as they often experience significant comorbidity including cardiovascular diseases that require anticoagulation. Patients with renal failure on new anticoagulants have experienced excessive bleeding which can be related to a changed pharmacokinetic profile of the compounds. However, the coagulation system itself, even without any interference with coagulation modifying drugs, is already profoundly changed during renal failure. Coagulation disorders with either episodes of severe bleeding or thrombosis represent an important cause for the morbidity and mortality of such patients. The underlying reasons for these coagulation disorders involve the changed interaction of different components of the coagulation system such as the coagulation cascade, the platelets and the vessel wall in the metabolic conditions of renal failure. Recent work provides evidence that new factors such as microparticles (MPs) can influence the coagulation system in patients with renal insufficiency through their potent procoagulatory effects. Interestingly, MPs may also contain microRNAs thus inhibiting the function of platelets, resulting in bleeding episodes. This review comprises the findings on the complex pathophysiology of coagulation disorders including new factors such as MPs and microRNAs in patients with renal insufficiency.
                Bookmark

                Author and article information

                Journal
                J Clin Med
                J Clin Med
                jcm
                Journal of Clinical Medicine
                MDPI
                2077-0383
                04 May 2019
                May 2019
                : 8
                : 5
                : 608
                Affiliations
                [1 ]Centre de Néphrologie et Transplantation Rénale, Hôpital de la conception AP-HM, 13005 Marseille, France; guillaume.lano@ 123456ap-hm.fr (G.L.); marion.sallee@ 123456ap-hm.fr (M.S.); marion.pelletier@ 123456ap-hm.fr (M.P.); megan.fraisse@ 123456ap-hm.fr (M.F.); philippe.brunet@ 123456ap-hm.fr (P.B.)
                [2 ]Faculty of Pharmacy, Aix Marseille Univ, INSERM, INRA, C2VN, 13005 Marseille, France; stanislas.bataille@ 123456sfr.fr (S.B.)
                [3 ]Elsan, Phocean Institute of Nephrology, Clinique Bouchard, 13008 Marseille, France
                [4 ]Hematology and Vascular Biology Department, Hôpital de la Conception, AP-HM, 13005 Marseille, France; yael.berda@ 123456ap-hm.fr (Y.B.-H.)
                Author notes
                [* ]Correspondence: stephane.burtey@ 123456univ-amu.fr ; Tel.: +33-491-383-044
                Author information
                https://orcid.org/0000-0003-1813-7884
                Article
                jcm-08-00608
                10.3390/jcm8050608
                6571831
                31060235
                e7b330b3-cc33-4a52-8d6e-71138794a0c4
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 08 April 2019
                : 02 May 2019
                Categories
                Article

                arteriovenous fistula,hemodialysis,mean platelet volume,thrombosis,end-stage renal disease

                Comments

                Comment on this article